{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:37:29Z","timestamp":1791405449677,"version":"4.3.3"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Exposure to radiation is related to breast cancer occurrence. While whether the radioiodine (RAI) increases the risk of second breast cancer (SBC) in female differentiated thyroid cancer (DTC) patients is not well addressed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients were identified from Surveillance, Epidemiology, and End Results database. At least a 5-year latency was guaranteed since exposure to RAI. Fine and Gray model was used to calculate the cumulative incidence and hazards ratios (HR) and 95% confidence interval (CI). Standardized incidence ratio (SIR) was calculated by Poisson regression analysis. Propensity score matching was used for match analysis. Survival analyses were performed by the Kaplan-Meier method and the log-rank test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 406 out of 16,850 patients in the RAI group and 733 out of 22,135 patients in the no RAI group developed SBC. The cumulative incidences of SBC were higher in patients with RAI compared with patients without RAI in the adolescent and young adult (AYA) group and the middle-aged adult group. In the AYA group, patients with RAI had increased HR (1.65; 95% CI, 1.33\u20132.05, <jats:italic>p<\/jats:italic>\u00a0&amp;lt;\u00a00.001) compared with those without RAI, and the HR increased slightly with latency. In addition, the SIR (1.21; 95% CI, 1.02\u20131.44, <jats:italic>p<\/jats:italic>\u00a0&amp;lt;\u00a00.05) increased compared with the general population. Whereas, in the middle-aged adult group, only a slightly higher HR (1.18) was found. The survival after SBC was inferior to those with matched only primary breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>RAI treatment increased the risk of SBC in female AYA DTC patients. A long-term follow-up should be performed in this population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.805194","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:49:02Z","timestamp":1643370542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult"],"prefix":"10.3389","volume":"12","author":[{"given":"Xianlan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11175","article-title":"Pure Versus Follicular Variant of Papillary Thyroid Carcinoma: Clinical Features, Prognostic Factors, Treatment, and Survival","volume":"97","author":"Zidan","year":"2003","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","article-title":"Prognostic Factors for Thyroid Carcinoma. A Population-Based Study of 15,698 Cases From the Surveillance, Epidemiology and End Results (SEER) Program 1973-1991","volume":"79","author":"Gilliland","year":"1997","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.09.001","article-title":"Intermediate and Long-Term Adverse Effects of Radioiodine Therapy for Differentiated Thyroid Carcinoma\u2013A Systematic Review","volume":"41","author":"Clement","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1154","article-title":"The Risk of Second Primary Malignancies Up to Three Decades After the Treatment of Differentiated Thyroid Cancer","volume":"93","author":"Brown","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-15-0234","article-title":"Iodide Transport and Breast Cancer","volume":"227","author":"Poole","year":"2015","journal-title":"J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.1611","article-title":"The Benefits and Risks of I-131 Therapy in Patients With Well-Differentiated Thyroid Cancer","volume":"19","author":"Van Nostrand","year":"2009","journal-title":"Thyroid"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00381","article-title":"Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey","volume":"11","author":"Reiners","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1667\/RR0763.1","article-title":"Solid Cancer Incidence in Atomic Bomb Survivors: 1958-1998","volume":"168","author":"Preston","year":"2007","journal-title":"Radiat Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3456-6","article-title":"The Association Between Breast Cancer and Thyroid Cancer: A Meta-Analysis","volume":"152","author":"Joseph","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-15-0833","article-title":"The Breast-Thyroid Cancer Link: A Systematic Review and Meta-Analysis","volume":"25","author":"Nielsen","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2015.10.009","article-title":"Breast Cancer in Thyroid Cancer Survivors: An Analysis of the Surveillance, Epidemiology, and End Results-9 Database","volume":"159","author":"Kuo","year":"2016","journal-title":"Surgery"},{"key":"B13","doi-asserted-by":"publisher","first-page":"8765369","DOI":"10.1155\/2018\/8765369","article-title":"Incidence of Second Malignancy in Patients With Papillary Thyroid Cancer From Surveillance, Epidemiology, and End Results 13 Dataset","volume":"2018","author":"Endo","year":"2018","journal-title":"J Thyroid Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29025","article-title":"Elevated Risks of Subsequent Primary Malignancies in Patients With Thyroid Cancer: A Nationwide, Population-Based Study in Korea","volume":"121","author":"Cho","year":"2015","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1089\/thy.2016.0481","article-title":"Trends of Second Primary Malignancy in Patients With Thyroid Cancer: A Population-Based Cohort Study in Israel","volume":"27","author":"Izkhakov","year":"2017","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0561","article-title":"A Possible Association Between Thyroid Cancer and Breast Cancer","volume":"25","author":"An","year":"2015","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/bjc.1984.13","article-title":"Multiple Primary Breast and Thyroid Cancer","volume":"49","author":"Ron","year":"1984","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.164830","article-title":"Risk of Breast Cancer in Patients With Thyroid Cancer Receiving or Not Receiving 131i Treatment: A Nationwide Population-Based Cohort Study","volume":"57","author":"Lin","year":"2016","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0392","article-title":"Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-Analysis","volume":"19","author":"Sawka","year":"2009","journal-title":"Thyroid"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000419","article-title":"Risk of Second Primary Breast Cancer After Radioactive Iodine Treatment in Thyroid Cancer: A Systematic Review and Meta-Analysis","volume":"37","author":"Zhang","year":"2016","journal-title":"Nucl Med Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second Primary Malignancies in Thyroid Cancer Patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21064","article-title":"Thyroid Cancer and Multiple Primary Tumors in the SEER Cancer Registries","volume":"117","author":"Ronckers","year":"2005","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/000348940611500806","article-title":"Risk of Second Primary Malignancy After Radioactive Iodine Treatment for Differentiated Thyroid Carcinoma","volume":"115","author":"Bhattacharyya","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0406","article-title":"The Risk of Second Cancers After Diagnosis of Primary Thyroid Cancer Is Elevated in Thyroid Microcarcinomas","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2014-2896","article-title":"Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer","volume":"100","author":"Ahn","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"djv314","DOI":"10.1093\/jnci\/djv314","article-title":"Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study","volume":"108","author":"Teng","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1991.261","article-title":"Cancer Risks in Thyroid Cancer Patients","volume":"64","author":"Hall","year":"1991","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3109\/02841869209088279","article-title":"Tumors After Radiotherapy for Thyroid Cancer. A Case-Control Study Within a Cohort of Thyroid Cancer Patients","volume":"31","author":"Hall","year":"1992","journal-title":"Acta Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11626","article-title":"The Risk of Multiple Primary Breast and Thyroid Carcinomas","volume":"98","author":"Adjadj","year":"2003","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70061-4","article-title":"Proportion of Second Cancers Attributable to Radiotherapy Treatment in Adults: A Cohort Study in the US SEER Cancer Registries","volume":"12","author":"Berrington de Gonzalez","year":"2011","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2031661","DOI":"10.1001\/jamanetworkopen.2020.31661","article-title":"Association of Radiotherapy for Rectal Cancer and Second Gynecological Malignant Neoplasms","volume":"4","author":"Guan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0460","article-title":"Management Guidelines for Children With Thyroid Nodules and Differentiated Thyroid Cancer","volume":"25","author":"Francis","year":"2015","journal-title":"Thyroid"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2712","article-title":"Tutorial in Biostatistics: Competing Risks and Multi-State Models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.21037\/atm.2018.07.38","article-title":"Overview of Model Validation for Survival Regression Model With Competing Risks Using Melanoma Study Data","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"key":"B35","unstructured":"RadRat Tool2020"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12581","article-title":"The Risk of Second Primary Malignancy Is Increased in Differentiated Thyroid Cancer Patients With a Cumulative (131)I Dose Over 37 GBq","volume":"83","author":"Khang","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.567385","article-title":"Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients","volume":"11","author":"Drozd","year":"2020","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.805194\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:49:07Z","timestamp":1643370547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.805194\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":37,"alternative-id":["10.3389\/fendo.2021.805194"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.805194","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"article-number":"805194"}}